About

Years: 2020 – 2021

Training Site: Infectious Diseases Institute Mulago

Country: Uganda

Mentors: Kelly Dooley, MD, MPH, PhD; Christine Sekaggya-Wiltshire, MBChB, MMed

Title: “Role of pharmacogenomics in Dolutegravir serum drug levels among HIV/TB co-infected persons on rifampicin in a pharmacokinetic clinical trial”

Program Objectives:

Aim 1: To describe UGT 1A1 polymorphisms among HIV infected patients in Uganda receiving rifampicin.

Aim 2: To investigate the effect of UGT 1A1 polymorphisms on dolutegravir pharmacokinetics among HIV infected patients in Uganda receiving rifampicin.

NIH Support: FIC-AIDS